BioCentury | Sep 22, 2016
Distillery Therapeutics

Therapeutics: Phosphoinositide 3-kinase class 2 subunit β polypeptide (PI3KC2B); myotubularin 1 (MTM1); phosphatidylinositol-3-phosphate (PI3P)

...Musculoskeletal disease INDICATION: Musculoskeletal Mouse and zebrafish studies suggest inhibiting PI3KC2B could help treat myotubular myopathy...
...by mutations in MTM1 . In a mouse model of the disease, muscle-specific knockout of PI3KC2B...
...normal PI3KC2B expression or vehicle. In a zebrafish model of myotubular myopathy, three inhibitors of PI3KC2B...
BioCentury | Jul 21, 2016
Distillery Therapeutics

Therapeutics: Glutamic-pyruvic transaminase 2 (GPT2); activating transcription factor 4 (ATF4); phosphoinositide 3-kinase catalytic subunit α polypeptide (PI3KC

Cancer INDICATION: Colorectal cancer Patient sample, cell culture and mouse studies suggest inhibiting GPT2 or ATF4 could help treat PI3KCA-mutant colorectal cancer. In tumor samples from colorectal cancer patients, GPT2 expression was higher in tumors...
Items per page:
1 - 2 of 2